Peer-reviewedLicence not stated
Vamorolone (Agamree): Indication: For the treatment of Duchenne muscular dystrophy in patients 4 years of age and older: Reimbursement Recommendation
Related
- Inebilizumab (Uplizna): Indication: As an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive: Reimbursement Recommendation
- Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation
- Intranasal epinephrine (Neffy): Indication: Emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis in adult and pediatric patients who weigh 30 kg or greater: Reimbursement Recommendation
- Inebilizumab (Uplizna): Indication: Adults with immunoglobulin G4-related disease: Reimbursement Recommendation
- Fracture morphology guides the selection of closed versus open reduction in straddle fractures: outcomes of an indication-based treatment strategy
BibTeX
@article{anon2026vamorolone,
title = {{Vamorolone (Agamree): Indication: For the treatment of Duchenne muscular dystrophy in patients 4 years of age and older: Reimbursement Recommendation}},
year = {2026},
month = sep,
url = {https://europepmc.org/article/MED/42899954},
}
RIS
TY - JOUR
TI - Vamorolone (Agamree): Indication: For the treatment of Duchenne muscular dystrophy in patients 4 years of age and older: Reimbursement Recommendation
PY - 2026
DA - 2026/09/01
UR - https://europepmc.org/article/MED/42899954
ER -